LBF20207PG22 - Revision history

Editor at 00:00, 17 January 2014

2014-01-17T00:00:00Z

@@ Line 20: / Line 20: @@
 |Biological Activity=Biological significance of prostaglandin D2 was unknown except anti-aggregatory and bronchoconstrictive activities [[Reference:Giles_H:Leff_P:,Prostaglandins,1988,35,277|{{RelationTable/GetFirstAuthor|Reference:Giles_H:Leff_P:,Prostaglandins,1988,35,277}}]]. Recently prostaglandin D2 has been noted as antineoplastic agent (actually attributed to  Delta 12-prostaglandin J2) [[Reference:Fukushima_M:,Prostaglandins Leukot. Essent. Fatty Acids,1992,47,1|{{RelationTable/GetFirstAuthor|Reference:Fukushima_M:,Prostaglandins Leukot. Essent. Fatty Acids,1992,47,1}}]][[Reference:Negishi_M:Koizumi_T:Ichikawa_A:,J. Lipid Mediat. Cell Signal.,1995,12,443|{{RelationTable/GetFirstAuthor|Reference:Negishi_M:Koizumi_T:Ichikawa_A:,J. Lipid Mediat. Cell Signal.,1995,12,443}}]] and as a sleep-inducing compound [[Reference:Hayaishi_O:,J. Biol. Chem.,1988,263,14593|{{RelationTable/GetFirstAuthor|Reference:Hayaishi_O:,J. Biol. Chem.,1988,263,14593}}]]. Prostaglandin D2 binds to a receptor with 7 transmembrane domains (DP) coupled to a Gs protein [[Reference:Negishi_M:Sugimoto_Y:Ichikawa_A:,Biochim. Biophys. Acta,1995,1259,109|{{RelationTable/GetFirstAuthor|Reference:Negishi_M:Sugimoto_Y:Ichikawa_A:,Biochim. Biophys. Acta,1995,1259,109}}]].
 |Genetic Information=cDNA and genomic DNA of prostaglandin D synthase were cloned [[Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257|{{RelationTable/GetFirstAuthor|Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257}}]]. cDNA for DP was isolated [[Reference:Negishi_M:Koizumi_T:Ichikawa_A:,J. Lipid Mediat. Cell Signal.,1995,12,443|{{RelationTable/GetFirstAuthor|Reference:Negishi_M:Koizumi_T:Ichikawa_A:,J. Lipid Mediat. Cell Signal.,1995,12,443}}]].
 }}
 {{Lipid/Footer}}

Editor at 08:23, 21 October 2010

2010-10-21T08:23:28Z

← Older revision		Revision as of 17:23, 21 October 2010
Line 6:		Line 6:
	\|LipidBank=XPR1301		\|LipidBank=XPR1301
	\|LipidMaps=LMFA03010004		\|LipidMaps=LMFA03010004
	\|SysName=7- [ 5S -Hydroxy-2R - (3S-hydroxy-1~~-trans~~-octenyl) -3-oxocyclopentan-1R -yl ] -5~~-cis~~-heptenoic acid		\|SysName=7- [5S -Hydroxy-2R - (3S-hydroxy-trans-1-octenyl) -3-oxocyclopentan-1R -yl] -cis-5-heptenoic acid
	\|Common Name=&&Prostaglandin D_2&&7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid&&		\|Common Name=&&Prostaglandin D_2&&7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid&&
	\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]		\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]

Editor at 03:01, 27 May 2010

2010-05-27T03:01:11Z

← Older revision		Revision as of 12:01, 27 May 2010
Line 7:		Line 7:
	\|LipidMaps=LMFA03010004		\|LipidMaps=LMFA03010004
	\|SysName=7- [ 5S -Hydroxy-2R - (3S-hydroxy-1-trans-octenyl) -3-oxocyclopentan-1R -yl ] -5-cis-heptenoic acid		\|SysName=7- [ 5S -Hydroxy-2R - (3S-hydroxy-1-trans-octenyl) -3-oxocyclopentan-1R -yl ] -5-cis-heptenoic acid
	\|Common Name=&&Prostaglandin D_2&&7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) ~~-yl ] -5 (Z) -heptenoic acid&&7- [ 5S -Hydroxy-2R - (3S-hydroxy-1(E) -octenyl) -3-oxocyclopentan-1R~~ -yl ] -5 (Z) -heptenoic acid&&		\|Common Name=&&Prostaglandin D_2&&7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid&&
	\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]		\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]
	\|Optical=[ alpha ]^{20}_D =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Optical=[ alpha ]^{20}_D =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]

Editor at 03:00, 27 May 2010

2010-05-27T03:00:31Z

← Older revision		Revision as of 12:00, 27 May 2010
Line 6:		Line 6:
	\|LipidBank=XPR1301		\|LipidBank=XPR1301
	\|LipidMaps=LMFA03010004		\|LipidMaps=LMFA03010004
	\|SysName=7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid		\|SysName=7- [ 5S -Hydroxy-2R - (3S-hydroxy-1-trans-octenyl) -3-oxocyclopentan-1R -yl ] -5-cis-heptenoic acid
	~~\|Common Name=~~&&~~Prostaglandin D_2~~&&		\|Common Name=&&Prostaglandin D_2&&7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid&&7- [ 5S -Hydroxy-2R - (3S-hydroxy-1(E) -octenyl) -3-oxocyclopentan-1R -yl ] -5 (Z) -heptenoic acid&&
	\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]		\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]
	\|Optical=[ alpha ]^{20}_D =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Optical=[ alpha ]^{20}_D =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]

Editor at 04:51, 21 April 2010

2010-04-21T04:51:25Z

← Older revision		Revision as of 13:51, 21 April 2010
Line 7:		Line 7:
	\|LipidMaps=LMFA03010004		\|LipidMaps=LMFA03010004
	\|SysName=7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid		\|SysName=7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid
	\|Common Name=&&~~PROSTAGLANDIN~~ D_2&&		\|Common Name=&&Prostaglandin D_2&&
	\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]		\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]
	\|Optical=[ alpha ]^{20}_D =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Optical=[ alpha ]^{20}_D =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]

Dbmanager at 21:00, 14 April 2010

2010-04-14T21:00:00Z

← Older revision		Revision as of 06:00, 15 April 2010
Line 7:		Line 7:
	\|LipidMaps=LMFA03010004		\|LipidMaps=LMFA03010004
	\|SysName=7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid		\|SysName=7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid
	\|Common Name=&&PROSTAGLANDIN D_2~~&&7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid~~&&		\|Common Name=&&PROSTAGLANDIN D_2&&
	\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]		\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]
	\|Optical=[ alpha ]^{20}_D =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Optical=[ alpha ]^{20}_D =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]

Dbmanager at 05:44, 26 February 2010

2010-02-26T05:44:15Z

← Older revision		Revision as of 14:44, 26 February 2010
Line 9:		Line 9:
	\|Common Name=&&PROSTAGLANDIN D_2&&7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid&&		\|Common Name=&&PROSTAGLANDIN D_2&&7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid&&
	\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]		\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]
	\|Optical=[ alpha ]X^{20}_D =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Optical=[ alpha ]^{20}_D =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]
	\|Solubility=ETHYL ACETATE,THF,CHLOROFORM [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Solubility=ETHYL ACETATE,THF,CHLOROFORM [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]
	\|Mass Spectra=m/e 334, 316, 246, 245, 191, 190, 161, 55 [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Mass Spectra=m/e 334, 316, 246, 245, 191, 190, 161, 55 [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]

Editor at 10:00, 25 February 2010

2010-02-25T10:00:10Z

← Older revision		Revision as of 19:00, 25 February 2010
Line 9:		Line 9:
	\|Common Name=&&PROSTAGLANDIN D_2&&7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid&&		\|Common Name=&&PROSTAGLANDIN D_2&&7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid&&
	\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]		\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]
	\|Optical=[ alpha ]X^~~20_D~~ =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Optical=[ alpha ]X^{20}_D =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]
	\|Solubility=ETHYL ACETATE,THF,CHLOROFORM [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Solubility=ETHYL ACETATE,THF,CHLOROFORM [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]
	\|Mass Spectra=m/e 334, 316, 246, 245, 191, 190, 161, 55 [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Mass Spectra=m/e 334, 316, 246, 245, 191, 190, 161, 55 [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]
	\|IR Spectra=KBr : 3400-2500, 1740, 1700, 975cm^- ^1 [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]		\|IR Spectra=KBr : 3400-2500, 1740, 1700, 975cm^{-1} [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]
	\|NMR Spectra=^1 H-NMR(270MHz, CDCl_3 ) : delta 5.63(dd,J=7 & 16Hz,1H,14-CH), 5.43(dd,J=16 & 8.5Hz,1H,13-CH), 4.47(m, 1H, 9-CH), 4.09(bq, J=7Hz, 1H, 15-CH), 2.87(dd, J=12 & 8.5Hz, 1H, 12-CH), 2.45(m, 2H, 10-CH2), 1.95(bm, 1H, 8-CH) [[Reference:Jenny_EF:Schaeublin_P:,Tetrah. Lett.,1974,,2235\|{{RelationTable/GetFirstAuthor\|Reference:Jenny_EF:Schaeublin_P:,Tetrah. Lett.,1974,,2235}}]]		\|NMR Spectra=^1 H-NMR(270MHz, CDCl_3 ) : delta 5.63(dd,J=7 & 16Hz,1H,14-CH), 5.43(dd,J=16 & 8.5Hz,1H,13-CH), 4.47(m, 1H, 9-CH), 4.09(bq, J=7Hz, 1H, 15-CH), 2.87(dd, J=12 & 8.5Hz, 1H, 12-CH), 2.45(m, 2H, 10-CH2), 1.95(bm, 1H, 8-CH) [[Reference:Jenny_EF:Schaeublin_P:,Tetrah. Lett.,1974,,2235\|{{RelationTable/GetFirstAuthor\|Reference:Jenny_EF:Schaeublin_P:,Tetrah. Lett.,1974,,2235}}]]
	\|Source=In most animal tissues prostanoids are synthesized enzymatically de novo upon physiological and pathological stimulations, and this is also the case of prostaglandin D2. Prostaglandin D2 is produced in barin, lung, spleen, mast cells and other tissues [[Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257\|{{RelationTable/GetFirstAuthor\|Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257}}]].		\|Source=In most animal tissues prostanoids are synthesized enzymatically de novo upon physiological and pathological stimulations, and this is also the case of prostaglandin D2. Prostaglandin D2 is produced in barin, lung, spleen, mast cells and other tissues [[Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257\|{{RelationTable/GetFirstAuthor\|Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257}}]].

Editor at 14:00, 19 February 2010

2010-02-19T14:00:10Z

Editor at 14:00, 19 February 2010

2010-02-19T14:00:00Z

← Older revision		Revision as of 14:44, 26 February 2010
Line 9:		Line 9:
	\|Common Name=&&PROSTAGLANDIN D_2&&7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid&&		\|Common Name=&&PROSTAGLANDIN D_2&&7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid&&
	\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]		\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]
	\|Optical=[ alpha ]X^{20}_D =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Optical=[ alpha ]^{20}_D =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]
	\|Solubility=ETHYL ACETATE,THF,CHLOROFORM [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Solubility=ETHYL ACETATE,THF,CHLOROFORM [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]
	\|Mass Spectra=m/e 334, 316, 246, 245, 191, 190, 161, 55 [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Mass Spectra=m/e 334, 316, 246, 245, 191, 190, 161, 55 [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]

← Older revision		Revision as of 19:00, 25 February 2010
Line 9:		Line 9:
	\|Common Name=&&PROSTAGLANDIN D_2&&7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid&&		\|Common Name=&&PROSTAGLANDIN D_2&&7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid&&
	\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]		\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]
	\|Optical=[ alpha ]X^~~20_D~~ =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Optical=[ alpha ]X^{20}_D =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]
	\|Solubility=ETHYL ACETATE,THF,CHLOROFORM [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Solubility=ETHYL ACETATE,THF,CHLOROFORM [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]
	\|Mass Spectra=m/e 334, 316, 246, 245, 191, 190, 161, 55 [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Mass Spectra=m/e 334, 316, 246, 245, 191, 190, 161, 55 [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]
	\|IR Spectra=KBr : 3400-2500, 1740, 1700, 975cm^- ^1 [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]		\|IR Spectra=KBr : 3400-2500, 1740, 1700, 975cm^{-1} [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]
	\|NMR Spectra=^1 H-NMR(270MHz, CDCl_3 ) : delta 5.63(dd,J=7 & 16Hz,1H,14-CH), 5.43(dd,J=16 & 8.5Hz,1H,13-CH), 4.47(m, 1H, 9-CH), 4.09(bq, J=7Hz, 1H, 15-CH), 2.87(dd, J=12 & 8.5Hz, 1H, 12-CH), 2.45(m, 2H, 10-CH2), 1.95(bm, 1H, 8-CH) [[Reference:Jenny_EF:Schaeublin_P:,Tetrah. Lett.,1974,,2235\|{{RelationTable/GetFirstAuthor\|Reference:Jenny_EF:Schaeublin_P:,Tetrah. Lett.,1974,,2235}}]]		\|NMR Spectra=^1 H-NMR(270MHz, CDCl_3 ) : delta 5.63(dd,J=7 & 16Hz,1H,14-CH), 5.43(dd,J=16 & 8.5Hz,1H,13-CH), 4.47(m, 1H, 9-CH), 4.09(bq, J=7Hz, 1H, 15-CH), 2.87(dd, J=12 & 8.5Hz, 1H, 12-CH), 2.45(m, 2H, 10-CH2), 1.95(bm, 1H, 8-CH) [[Reference:Jenny_EF:Schaeublin_P:,Tetrah. Lett.,1974,,2235\|{{RelationTable/GetFirstAuthor\|Reference:Jenny_EF:Schaeublin_P:,Tetrah. Lett.,1974,,2235}}]]
	\|Source=In most animal tissues prostanoids are synthesized enzymatically de novo upon physiological and pathological stimulations, and this is also the case of prostaglandin D2. Prostaglandin D2 is produced in barin, lung, spleen, mast cells and other tissues [[Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257\|{{RelationTable/GetFirstAuthor\|Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257}}]].		\|Source=In most animal tissues prostanoids are synthesized enzymatically de novo upon physiological and pathological stimulations, and this is also the case of prostaglandin D2. Prostaglandin D2 is produced in barin, lung, spleen, mast cells and other tissues [[Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257\|{{RelationTable/GetFirstAuthor\|Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257}}]].

← Older revision		Revision as of 23:00, 19 February 2010
Line 9:		Line 9:
	\|Common Name=&&PROSTAGLANDIN D_2&&7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid&&		\|Common Name=&&PROSTAGLANDIN D_2&&7- [ 5 (S) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -3-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid&&
	\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]		\|Melting Point=68°C [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]
	\|Optical=[alpha]X^20_D =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Optical=[ alpha ]X^20_D =9° (C=2.11,THF) [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]
	\|Solubility=ETHYL ACETATE,THF,CHLOROFORM [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Solubility=ETHYL ACETATE,THF,CHLOROFORM [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]
	\|Mass Spectra=m/e 334, 316, 246, 245, 191, 190, 161, 55 [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]		\|Mass Spectra=m/e 334, 316, 246, 245, 191, 190, 161, 55 [[Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625\|{{RelationTable/GetFirstAuthor\|Reference:Ogawa_Y:Nunomoto_M:Shibasaki_M:,J. Org. Chem.,1986,51,1625}}]]
	\|IR Spectra=KBr : 3400-2500, 1740, 1700, 975cm^- ^1 [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]		\|IR Spectra=KBr : 3400-2500, 1740, 1700, 975cm^- ^1 [[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]]
	\|NMR Spectra=^1 H-NMR(270MHz, CDCl_3 ) : delta 5.63(dd,J=7 & 16Hz,1H,14-CH), 5.43(dd,J=16 & 8.5Hz,1H,13-CH), 4.47(m, 1H, 9-CH), 4.09(bq, J=7Hz, 1H, 15-CH), 2.87(dd, J=12 & 8.5Hz, 1H, 12-CH), 2.45(m, 2H, 10-CH2), 1.95(bm, 1H, 8-CH) [[Reference:Jenny_EF:Schaeublin_P:,Tetrah. Lett.,1974,,2235\|{{RelationTable/GetFirstAuthor\|Reference:Jenny_EF:Schaeublin_P:,Tetrah. Lett.,1974,,2235}}]]		\|NMR Spectra=^1 H-NMR(270MHz, CDCl_3 ) : delta 5.63(dd,J=7 & 16Hz,1H,14-CH), 5.43(dd,J=16 & 8.5Hz,1H,13-CH), 4.47(m, 1H, 9-CH), 4.09(bq, J=7Hz, 1H, 15-CH), 2.87(dd, J=12 & 8.5Hz, 1H, 12-CH), 2.45(m, 2H, 10-CH2), 1.95(bm, 1H, 8-CH) [[Reference:Jenny_EF:Schaeublin_P:,Tetrah. Lett.,1974,,2235\|{{RelationTable/GetFirstAuthor\|Reference:Jenny_EF:Schaeublin_P:,Tetrah. Lett.,1974,,2235}}]]
	\|Source=In most animal tissues prostanoids are synthesized enzymatically de novo upon physiological and pathological stimulations, and this is also the case of prostaglandin D2. Prostaglandin D2 is produced in barin, lung, spleen, mast cells and other tissues [[Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257\|{{RelationTable/GetFirstAuthor\|Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257}}]].		\|Source=In most animal tissues prostanoids are synthesized enzymatically de novo upon physiological and pathological stimulations, and this is also the case of prostaglandin D2. Prostaglandin D2 is produced in barin, lung, spleen, mast cells and other tissues [[Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257\|{{RelationTable/GetFirstAuthor\|Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257}}]].
	\|Chemical Synthesis=[[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]] {{Image200\|LBF20207PG22FT0001.gif}}		\|Chemical Synthesis=[[Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115\|{{RelationTable/GetFirstAuthor\|Reference:Hayashi_M:Tanouchi_T:,J. Org. Chem.,1973,38,2115}}]] {{Image200\|LBF20207PG22FT0001.gif}}
	\|Metabolism=Prostaglandin D2 is produced by isomerization of 9,11-endoperoxide of prostaglandin H2. There are two isozymes of prostaglandin D synthase (hematopoietic type and lipocalin type) distinguished by glutathione reequirement and effect of inhibitor [[Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257\|{{RelationTable/GetFirstAuthor\|Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257}}]]. Prostaglandin D2 is either reduced to ~~9alpha~~,~~11beta~~-prostaglandin F or oxidized to 15-keto-prostaglandin D2 by a specific dehydrogenase [[Reference:Giles_H:Leff_P:,Prostaglandins,1988,35,277\|{{RelationTable/GetFirstAuthor\|Reference:Giles_H:Leff_P:,Prostaglandins,1988,35,277}}]]. Non-enzymatic transformation of prostaglandin D2 produces anti-neoplastic ~~Delta12~~-prostaglandin J2 [[Reference:Negishi_M:Koizumi_T:Ichikawa_A:,J. Lipid Mediat. Cell Signal.,1995,12,443\|{{RelationTable/GetFirstAuthor\|Reference:Negishi_M:Koizumi_T:Ichikawa_A:,J. Lipid Mediat. Cell Signal.,1995,12,443}}]].		\|Metabolism=Prostaglandin D2 is produced by isomerization of 9,11-endoperoxide of prostaglandin H2. There are two isozymes of prostaglandin D synthase (hematopoietic type and lipocalin type) distinguished by glutathione reequirement and effect of inhibitor [[Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257\|{{RelationTable/GetFirstAuthor\|Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257}}]]. Prostaglandin D2 is either reduced to 9 alpha ,11 beta -prostaglandin F or oxidized to 15-keto-prostaglandin D2 by a specific dehydrogenase [[Reference:Giles_H:Leff_P:,Prostaglandins,1988,35,277\|{{RelationTable/GetFirstAuthor\|Reference:Giles_H:Leff_P:,Prostaglandins,1988,35,277}}]]. Non-enzymatic transformation of prostaglandin D2 produces anti-neoplastic Delta 12-prostaglandin J2 [[Reference:Negishi_M:Koizumi_T:Ichikawa_A:,J. Lipid Mediat. Cell Signal.,1995,12,443\|{{RelationTable/GetFirstAuthor\|Reference:Negishi_M:Koizumi_T:Ichikawa_A:,J. Lipid Mediat. Cell Signal.,1995,12,443}}]].
	\|Symbol=PGD2		\|Symbol=PGD2
	\|Biological Activity=Biological significance of prostaglandin D2 was unknown except anti-aggregatory and bronchoconstrictive activities [[Reference:Giles_H:Leff_P:,Prostaglandins,1988,35,277\|{{RelationTable/GetFirstAuthor\|Reference:Giles_H:Leff_P:,Prostaglandins,1988,35,277}}]]. Recently prostaglandin D2 has been noted as antineoplastic agent (actually attributed to ~~Delta12~~-prostaglandin J2) [[Reference:Fukushima_M:,Prostaglandins Leukot. Essent. Fatty Acids,1992,47,1\|{{RelationTable/GetFirstAuthor\|Reference:Fukushima_M:,Prostaglandins Leukot. Essent. Fatty Acids,1992,47,1}}]][[Reference:Negishi_M:Koizumi_T:Ichikawa_A:,J. Lipid Mediat. Cell Signal.,1995,12,443\|{{RelationTable/GetFirstAuthor\|Reference:Negishi_M:Koizumi_T:Ichikawa_A:,J. Lipid Mediat. Cell Signal.,1995,12,443}}]] and as a sleep-inducing compound [[Reference:Hayaishi_O:,J. Biol. Chem.,1988,263,14593\|{{RelationTable/GetFirstAuthor\|Reference:Hayaishi_O:,J. Biol. Chem.,1988,263,14593}}]]. Prostaglandin D2 binds to a receptor with 7 transmembrane domains (DP) coupled to a Gs protein [[Reference:Negishi_M:Sugimoto_Y:Ichikawa_A:,Biochim. Biophys. Acta,1995,1259,109\|{{RelationTable/GetFirstAuthor\|Reference:Negishi_M:Sugimoto_Y:Ichikawa_A:,Biochim. Biophys. Acta,1995,1259,109}}]].		\|Biological Activity=Biological significance of prostaglandin D2 was unknown except anti-aggregatory and bronchoconstrictive activities [[Reference:Giles_H:Leff_P:,Prostaglandins,1988,35,277\|{{RelationTable/GetFirstAuthor\|Reference:Giles_H:Leff_P:,Prostaglandins,1988,35,277}}]]. Recently prostaglandin D2 has been noted as antineoplastic agent (actually attributed to Delta 12-prostaglandin J2) [[Reference:Fukushima_M:,Prostaglandins Leukot. Essent. Fatty Acids,1992,47,1\|{{RelationTable/GetFirstAuthor\|Reference:Fukushima_M:,Prostaglandins Leukot. Essent. Fatty Acids,1992,47,1}}]][[Reference:Negishi_M:Koizumi_T:Ichikawa_A:,J. Lipid Mediat. Cell Signal.,1995,12,443\|{{RelationTable/GetFirstAuthor\|Reference:Negishi_M:Koizumi_T:Ichikawa_A:,J. Lipid Mediat. Cell Signal.,1995,12,443}}]] and as a sleep-inducing compound [[Reference:Hayaishi_O:,J. Biol. Chem.,1988,263,14593\|{{RelationTable/GetFirstAuthor\|Reference:Hayaishi_O:,J. Biol. Chem.,1988,263,14593}}]]. Prostaglandin D2 binds to a receptor with 7 transmembrane domains (DP) coupled to a Gs protein [[Reference:Negishi_M:Sugimoto_Y:Ichikawa_A:,Biochim. Biophys. Acta,1995,1259,109\|{{RelationTable/GetFirstAuthor\|Reference:Negishi_M:Sugimoto_Y:Ichikawa_A:,Biochim. Biophys. Acta,1995,1259,109}}]].
	\|Genetic Information=cDNA and genomic DNA of prostaglandin D synthase were cloned [[Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257\|{{RelationTable/GetFirstAuthor\|Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257}}]]. cDNA for DP was isolated [[Reference:Negishi_M:Koizumi_T:Ichikawa_A:,J. Lipid Mediat. Cell Signal.,1995,12,443\|{{RelationTable/GetFirstAuthor\|Reference:Negishi_M:Koizumi_T:Ichikawa_A:,J. Lipid Mediat. Cell Signal.,1995,12,443}}]].		\|Genetic Information=cDNA and genomic DNA of prostaglandin D synthase were cloned [[Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257\|{{RelationTable/GetFirstAuthor\|Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257}}]]. cDNA for DP was isolated [[Reference:Negishi_M:Koizumi_T:Ichikawa_A:,J. Lipid Mediat. Cell Signal.,1995,12,443\|{{RelationTable/GetFirstAuthor\|Reference:Negishi_M:Koizumi_T:Ichikawa_A:,J. Lipid Mediat. Cell Signal.,1995,12,443}}]].
	}}		}}

	{{Lipid/Footer}}		{{Lipid/Footer}}